Prothena Corporation plc (PRTA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $8.58 (+1.42%), Market cap $0.47B, 52-week low–high $4.58 ~ $11.51.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for th
Financial statements, price targets, institutional (13F) holdings and related news for Prothena Corporation plc are updated in real time on BlackAll Trade.
Prothena Corporation plc trades at $8.58 (+1.42%). Real-time quotes and charts are available on BlackAll Trade.
Prothena Corporation plc has a market cap of about $0.47B.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline i